Publications by authors named "L H Rosenberger"
Background: Flat epithelial atypia (FEA), a rare breast proliferative lesion, is often diagnosed following core biopsy (CB) of mammographic microcalcifications. In the prospective multi-institution TBCRC 034 trial, we investigate the upgrade rate to ductal carcinoma in situ (DCIS) or invasive cancer following excision for patients diagnosed with FEA on CB.
Patients And Methods: Patients with a breast imaging reporting and data system (BI-RADS) ≤ 4 imaging abnormality and a concordant CB diagnosis of FEA were identified for excision.
Article Synopsis
- * A study analyzed 57 MPT samples using various genomic and immunohistochemical techniques, revealing low HER2 expression compared to common breast cancer, and identified frequent genetic alterations among different tumor sites.
- * The research emphasizes the potential of next-generation sequencing (NGS) to find actionable genetic changes, supporting its role in MPT treatment decisions and highlighting the need for further MPT molecular studies.
Article Synopsis
- Cancer-specific T cells often fail to eliminate tumors, so researchers explored using CD4 T cell receptors (CD4TCRs) from tumor-bearers for new treatments.
- They focused on TCRs that target unique neoantigens presented by the surrounding tissue of MHC class II-negative cancer cells, testing the 11 most common TCRs.
- Some TCRs shared similar structures despite different sequences, effectively attacking tumors and reversing tumor progression; choosing TCRs based on their genetic similarities may enhance therapeutic success.
Germline genetic mutations in a multi-center cohort of 248 phyllodes tumors.
Breast Cancer Res Treat
September 2024
Article Synopsis
- - The study aimed to investigate the prevalence of pathogenic (P) or likely pathogenic (LP) genetic mutations in women with phyllodes tumors (PT), highlighting the need for more research in this area.
- - Involving 274 women, the research found that 14.1% had P/LP variants, particularly in genes linked to autosomal dominant cancer conditions, like CHEK2, ATM, and RAD51D.
- - The findings suggest that genetic testing could be beneficial for women with PT to guide screening and treatment, even though current national guidelines do not address this necessity.
Background: Axillary management after neoadjuvant chemotherapy (NAC) is evolving but axillary lymph node dissection (ALND) remains the standard of care for patients with residual nodal disease. The results of the Alliance A011202 trial evaluating the oncologic safety of ALND omission in this cohort are pending but we hypothesize that ALND omission is already increasing.
Methods: The National Cancer Database was queried to identify patients diagnosed with cT1-3N1M0 breast cancer who underwent NAC and had residual nodal disease (ypN1mi-2) from 2012 to 2021.